



March 23, 2026

Dear Esteemed Shareholders,

It is with the utmost and ineffable pleasure that I hereby announce a transaction of considerable significance and distinction: our Company has successfully acquired a commanding 60% stake in Acsapharm Ltd, United Kingdom.

The acquisition has been concluded at a valuation of USD 450,000, settled in full through the allocation of USD 450,000 in our non-voting shares—an arrangement reflective of both our strategic foresight and financial sophistication.

In the wake of this acquisition, we shall proceed with a series of decisive enhancements to the corporate structure of Acsapharm Ltd, including:

The relocation of its registered office;

The appointment of a newly constituted Board of Directors;

The designation of new accounting leadership.

Acsapharm Ltd holds the duly registered trademark “Acsapharm”, a valuable asset that will serve as the cornerstone of our forthcoming initiatives.

Our ambition — supported by distinguished research and manufacturing partners — is to introduce a pioneering and exceptionally efficacious line of anti-ageing products. These offerings, of the highest conceivable calibre, shall be distributed through luxury hotels and endorsed by a select cadre of professional ambassadors.

Allow me to reiterate my profound gratitude for the confidence you have placed in our leadership. It is a trust we honor with unwavering commitment and elevated vision.

With my highest regards,

All the best

Giuseppe Zeno
President